Piramal Pharma Limited Transitions to Biomass Boilers for Sustainability Efforts
Piramal Pharma Limited (NSE: PPLPHARMA, BSE: 543635) has recently embarked on an ambitious journey towards sustainability by upgrading its coal-fired steam boiler at its Digwal facility to operate on biomass briquettes. This transition marks a pivotal moment in the company's environmental efforts, reinforcing its commitment to improving its carbon footprint while setting new benchmarks within the pharmaceutical industry for eco-friendly practices.
In a statement from Nandini Piramal, Chairperson of Piramal Pharma, she highlighted that this move is a testament to the company's dedication to reducing its ecological impact while championing sustainable production methods. "Aligning our goals with global climate frameworks enables us to contribute to a greener future for generations to come," she affirmed.
The strategic upgrade is anticipated to result in the avoidance of approximately 24,000 tons of CO2 emissions annually, amounting to about 17% of the company's total emissions. This shift supports Piramal's goal of reducing Scope 1 and 2 greenhouse gas emissions by 42% by the year 2030. The utilization of biomass briquettes, which are compressed blocks made from agricultural waste, underscores the principles of a circular economy by recycling organic by-products, reducing waste, and promoting sustainability.
Peter DeYoung, CEO of Piramal Global Pharma, remarked on the significance of this initiative, stating that it not only highlights the company’s focus on environmental stewardship but also showcases innovative operational practices. "By transitioning to biomass briquettes, we significantly cut down our greenhouse gas emissions and set new industry standards for responsible pharmaceutical manufacturing," he stated.
The move is positioned as a strong alignment with global sustainability goals, showcasing how pharmaceutical companies can implement effective solutions for climate action while maintaining operational excellence. Piramal Pharma Limited's initiative exemplifies its commitment to responsible growth through environmentally friendly practices, contributing to a greener future.
Piramal Pharma Limited, listed as PPL (NSE: PPLPHARMA, BSE: 543635), operates a vast network across 17 global development and manufacturing sites, offering a range of differentiated products and services. The company’s operations encompass Piramal Pharma Solutions (PPS), a comprehensive contract development and manufacturing organization, and Piramal Critical Care (PCC), which focuses on complex generics for healthcare settings, as well as its consumer healthcare arm in India, delivering wellness products. Notably, an affiliate of PPL, Abbvie Therapeutics India Private Limited, stands out as a leading player in the ophthalmology sector within the Indian pharmaceutical market.
Further details can be found on Piramal Pharma's LinkedIn page or through their official website. This monumental move towards biomass fuel is just one of the many steps Piramal Pharma is taking towards a more sustainable and responsible operational model in the competitive pharmaceutical landscape.
In a statement from Nandini Piramal, Chairperson of Piramal Pharma, she highlighted that this move is a testament to the company's dedication to reducing its ecological impact while championing sustainable production methods. "Aligning our goals with global climate frameworks enables us to contribute to a greener future for generations to come," she affirmed.
The strategic upgrade is anticipated to result in the avoidance of approximately 24,000 tons of CO2 emissions annually, amounting to about 17% of the company's total emissions. This shift supports Piramal's goal of reducing Scope 1 and 2 greenhouse gas emissions by 42% by the year 2030. The utilization of biomass briquettes, which are compressed blocks made from agricultural waste, underscores the principles of a circular economy by recycling organic by-products, reducing waste, and promoting sustainability.
Peter DeYoung, CEO of Piramal Global Pharma, remarked on the significance of this initiative, stating that it not only highlights the company’s focus on environmental stewardship but also showcases innovative operational practices. "By transitioning to biomass briquettes, we significantly cut down our greenhouse gas emissions and set new industry standards for responsible pharmaceutical manufacturing," he stated.
The move is positioned as a strong alignment with global sustainability goals, showcasing how pharmaceutical companies can implement effective solutions for climate action while maintaining operational excellence. Piramal Pharma Limited's initiative exemplifies its commitment to responsible growth through environmentally friendly practices, contributing to a greener future.
About Piramal Pharma Limited
Piramal Pharma Limited, listed as PPL (NSE: PPLPHARMA, BSE: 543635), operates a vast network across 17 global development and manufacturing sites, offering a range of differentiated products and services. The company’s operations encompass Piramal Pharma Solutions (PPS), a comprehensive contract development and manufacturing organization, and Piramal Critical Care (PCC), which focuses on complex generics for healthcare settings, as well as its consumer healthcare arm in India, delivering wellness products. Notably, an affiliate of PPL, Abbvie Therapeutics India Private Limited, stands out as a leading player in the ophthalmology sector within the Indian pharmaceutical market.
Further details can be found on Piramal Pharma's LinkedIn page or through their official website. This monumental move towards biomass fuel is just one of the many steps Piramal Pharma is taking towards a more sustainable and responsible operational model in the competitive pharmaceutical landscape.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.